• about us
• allosteric modulation
• pipeline
• key indications
• business development
• investor center
• press releases
• careers
• contact

mGluR4 PAM

Positive allosteric modulators (PAM) of the metabotropic glutamate receptor 4 (mGluR4) have potential as a treatment for Parkinson's disease. The mGluR4 PAM program is in lead optimization and is the subject of a collaboration with Merck & Co., Inc.

mGluRs & parkinson's disease